Novo Nordisk A Fs traded at $111.64 this Friday July 1st, increasing $0.21 or 0.19 percent since the previous trading session. Looking back, over the last four weeks, Novo Nordisk A Fs gained 0.90 percent. Over the last 12 months, its price rose by 31.64 percent. Looking ahead, we forecast Novo Nordisk A Fs to be priced at 107.87 by the end of this quarter and at 96.06 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
111.64
Daily Change
0.19%
Yearly
31.64%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Aurora Cannabis Inc 1.70 -0.06 -3.41% -83.98%
ANI Pharmaceuticals 31.54 1.87 6.29% -10.00%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
Corcept Therapeutics 25.44 1.66 6.98% 14.03%
Catalent 107.02 -0.27 -0.25% -3.69%
Endo International 0.57 0.10 22.42% -86.74%
GlaxoSmithKline 1,785.60 20.00 1.13% 24.19%
Horizon Pharma 80.84 1.08 1.35% -15.68%
Jazz Pharmaceuticals 158.58 2.57 1.65% -12.63%
Lannett 0.56 -0.02 -3.46% -87.85%
Eli Lilly 324.71 0.48 0.15% 38.79%
Merck & Co 92.42 1.25 1.37% 17.58%
Nektar Therapeutics 3.75 -0.05 -1.32% -78.08%
Novartis 80.33 -0.52 -0.64% -4.96%
Novo Nordisk A Fs 111.64 0.21 0.19% 31.64%
Phibro Animal Health 19.59 0.46 2.40% -33.68%
Prestige Brands 59.58 0.78 1.33% 14.14%
Pacira 57.85 -0.45 -0.77% -2.41%
Powershares High Yield Orate Bond Portfolio 16.99 0.14 0.83% -13.32%
Perrigo 41.02 0.45 1.11% -12.56%
Drreddys Laboratories 55.84 0.45 0.81% -25.83%
Sanofi 97.52 1.18 1.22% 10.94%
Supernus Pharmaceuticals 29.35 0.43 1.49% -3.36%
Teva Pharmaceutical Industries 7.89 0.37 4.92% -19.74%
United States Oil Fund 81.67 1.32 1.64% 60.36%
Bausch Health Companies Inc 10.76 -0.22 -2.00% -70.77%
Canopy Growth Corp 3.66 -0.83 -18.49% -87.25%
Zoetis 174.21 2.32 1.35% -9.60%


Novo Nordisk A Fs
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.